Maxivision Eye Hospitals Charts Aggressive Gujarat Expansion; to Invest ₹150 Cr in 2 Yrs

Why It Matters

The infusion of capital accelerates access to specialized eye care in a high‑growth market, positioning Maxivision as a leading regional player and potentially reshaping competitive dynamics in Indian ophthalmology.

Key Takeaways

• ₹150 cr (~$18 M) investment targets 10 new Gujarat hospitals.
• Doctor‑partnership model expands Maxivision’s presence across regional markets.
• Collaboration with SRG Eye Hospital adds five Ahmedabad locations.
• Plans include entry into Karnataka, Goa, Madhya Pradesh, Odisha.
• Network will double from 10 to 20 facilities by 2028.

Pulse Analysis

India's ophthalmology sector is booming, driven by an aging population, rising diabetes rates, and increasing awareness of preventable blindness. According to the National Programme for Control of Blindness, demand for cataract surgery and refractive procedures is projected to grow at double‑digit rates over the next five years. Private chains that can deliver high‑volume, high‑quality care are attracting both patients and investors. Maxivision, founded in 2005, has leveraged a doctor‑partnership model to scale rapidly in southern states, establishing a reputation for advanced technology and cost‑effective services.

The latest ₹150 crore commitment focuses on Gujarat, a state with a population exceeding 70 million and a per‑capita income above the national average. By expanding from ten to twenty hospitals, Maxivision aims to capture a larger share of the state's outpatient eye‑care market, which is estimated at $1.2 billion annually. The partnership with SRG Eye Hospital, a well‑known local provider, will fast‑track five new Ahmedabad sites, reducing the time and capital required for greenfield construction. Simultaneously, the company is evaluating Vapi and Vadodara, cities with growing middle‑class demographics that favor private specialty care.

Beyond Gujarat, Maxivision’s aggressive rollout signals a broader shift toward consolidation in Indian healthcare, where regional chains are increasingly using partnership models to overcome talent shortages and regulatory hurdles. The planned entry into Karnataka, Goa, Madhya Pradesh and Odisha diversifies its geographic risk and opens cross‑selling opportunities for ancillary services such as retinal imaging and tele‑ophthalmology. Competitors like Sankara Nethralaya and Apollo Eye Hospitals may feel pressure to accelerate their own expansion or deepen alliances. For investors, the capital‑intensive but high‑margin eye‑care niche offers a compelling growth story, provided execution matches the ambitious timeline.